| 08.30-10.30 |
COMUNICACIONES ORALES
Auditorio
CO-01 a CO-10
Moderadores: Julià Blanco y Esteban Martínez
- CO-01
High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4, and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study
- CO-02
HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen
- CO-03
Changes in renal laboratory parameters and bone mineral density in treatment-naïve HIV-1- infected adolescents initiating therapy with INSTI-based single-tablet regimens containing tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF)
- CO-04
Screening of several polyanionic carbosilane dendrimers with antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
- CO-05
Implicación del miRNA-33 en el eflujo de colesterol mediado por ABCA1 en macrófagos infectados por VIH
- CO-06
The HDAC6/APOBEC3G complex regulates HIV‑1 infectiveness by inducing Vif autophagic degradation.
- CO-07
Impact of late presentation on short, mid and long-term mortality and on causes of death in Spain (2004-2013).
- CO-08
Adquisición de VIH en inmigrantes que viven en Europa: resultados del Estudio aMASE (Avanzando en el acceso de los inmigrantes a los servicios de salud en Europa)
- CO-09
Incidence of de novo Malignancies in HIV-Infected Liver Transplant Recipients
- CO-10
Situación clínica de pacientes coinfectados VIH-VHC vs. Monoinfectados VIH de transmisión vertical en el momento del paso a unidades de adultos
|
| 10.30-11.00 |
Pausa café
Hall Recepción Congresos
Defensa a pie de póster. Códigos de presentación IMPARES |
| 11.00-12.15 |
SESIONES PLENARIAS
Auditorio
Moderadores: Peré Domingo y María Ángeles Muñoz
|
| 12.15-13.45 |
MESA DEBATE 1
Auditorio
Futuro de las Unidades de VIH en España
Moderadores: Santiago Moreno y Rafael Rubio
|
| 12.15-13.45 |
MESA REDONDA INVESTIGACIÓN BÁSICA 1
Sala Postdam-Baden-Dresden
Vacunas
Moderadores: José Miguel Benito y Montserrat Plana
|
| 13.45-15.00 |
Almuerzo
Sala Venecia-Milán |
| 15.00-16.45 |
SESIONES PARALELAS DE POSTERS DISCUTIDOS
PO-01 a PO-10
Auditorio
Moderadores: José Ignacio Bernardino y Rosario Palacios
- PO-01
Elvitegravir concentrations in seminal plasma in HIV-1 infected patients
- PO-02
Efficacy and Safety of Doravirine 100mg QD or Efavirenz 600mg QD with TDF/FTC in ART-Naive HIV-Infected Patients: Week 24 Results
- PO-03
Dual Treatment with Atazanavir/r+3TC vs. Triple Treatment with Atazanavir/r+2 nucleos(t)ides in virologically stable patients with HIV-1 (SALT study): 96-week results from a randomised, open label, non-inferiority trial
- PO-04
Superior Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-1-infected, virologically suppressed subjects switched from PI and NNRTI-based regimens: Pooled results of STRATEGY-PI and STRATEGY-NNRTI (Week 96)
- PO-05
Evolución de las resistencias primarias y mutaciones en pacientes VIH naive en CoRIS en el período 2007-2015
- PO-06
The pharmacokinetics of tenofovir and tenofovir diphosphate following administration of tenofovir alafenamide versus tenofovir disoproxil fumarate
- PO-07
Elvitegravir (EVG) / cobicistat (COBI) / emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) is superior to ritonavir (RTV) boosted atazanavir (ATV) plus FTC/TDF in treatment naïve women with HIV-1 infection (WAVES Study
- PO-08
Switching from a Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to a Tenofovir Alafenamide (TAF)-Based Regimen: Data in Virologically Suppressed Adults Through 48 Weeks of Treatment
- PO-09
Safety of Once Daily Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide in Patients with GFR less than 50 mL/min: 48 Week Results
- PO-10
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression: a 24-week pilot study.
PO-11 a PO-20
Sala Postdam-Baden-Dresden
Moderadores: Teresa Cuevas y Luis Cecilio López Galíndez
- PO-11
Epidemiología molecular de VIH-1 en el Sur de España (2014-2015). Aparición de la variante CRF19_cpx; características clínico-epidemiológicas, virológicas y filogenéticas.
- PO-12
APOBEC es el principal determinante in vivo de la tasa de mutación de VIH-1
- PO-13
Influencia del uso de pares de codones en la capacidad de evolución del virus de la inmunodeficiencia humana de tipo 1
- PO-14
High Rate of Transmission Clusters among Men Who Have Sex with Men (MSM) with Acute-recent HIV Infection in Barcelona
- PO-15
Dendrímeros polianiónicos carbosilanos combinados con antirretrovirales mantienen su eficacia antiviral VIH en presencia de las fibrillas amiloides del semen (SEVI)
- PO-16
Detection of broadly neutralizing activity within the first six months of HIV-1 infection
- PO-17
Balance entre la activación y la regulación de la respuesta de células T CD8 específicas de VIH tras la vacunación terapéutica con MVA-B
- PO-18
Generation, optimization and characterization of VLP (Virus Like Particles) of HIV-1
- PO-19
Treatment with Dasatinib makes the peripheral blood lymphocytes from patients with chronic myeloid leukemia resistant to HIV-1 infection
- PO-20
Caracterización virológica de pacientes Controladores de Elite que pierden el control
|
| 16.45-17.15 |
Pausa café
Hall Recepción Congresos |
| 17.15-19.00 |
CONFERENCIAS ESPECIALES
Auditorio
Moderadores: Fernando Lozano y Mª Jesús Téllez
|
